In another example, an anti-CD33 x anti-CD3 BsAb could successfully redirect cytotoxic T cells to acute myeloid leukemia (AML) cells leading to efficient killing of residual AML cells which frequently go unaffected by standard therapies and often lead to tumor relapse36. This evidence concerns the gene CD33 and acute myeloid leukemia.